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Introduction
Extensive research over the past decade has led to 
major advances in our understanding of the importance 
of vitamin D in health and disease. A PubMed search, 
using the term “vitamin D”, limited to English articles 
that have been published in the past five years, 
revealed over 10 000 results. This renewed interest may 
be attributed to large studies that confirm the high 
level of nutritional vitamin D deficiency worldwide, to 
observational studies and metaanalyses that show a 
strong association between vitamin D deficiency and 
various chronic diseases, as well as to new insights that 
have emerged regarding the autocrine, paracrine 
and nonhormonal functions of activated vitamin D 
in humans.1 The above information explosion poses 
a challenge for clinicians. This article aims to provide 
a brief review of the issues that relate to vitamin D 
deficiency in the South African context.
Overview of vitamin D metabolism
Vitamin D exists in two forms: D2 (ergocalciferol) and D3 
(cholecalciferol). There are also numerous circulating 
metabolites in humans. Vitamin D3 is produced in 
the skin under the influence of ultraviolet light (80%), 
or can be obtained from the diet (fatty fish and egg 
yolks). Vitamin D2 is found in some plant sources and 
manufactured commercially by the irradiation of 
ergosterol produced by yeast.2 Supplementation can 
either be with vitamin D2 or D3. Both forms can be 
stored in adipose tissue or can undergo hydroxylation 
in the liver, whereby 25-hydroxyvitamin D 25 (OH) 
vitamin D (calcidiol) [25(OH)D] is produced. This form 
is converted in the kidney (via 1α hydroxylase) to 
1,25(OH)2 vitamin D (calcitriol), the biologically 
active form of vitamin D.
The vitamin D receptor is a nuclear receptor of the 
thyroid hormone receptor superfamily. All tissues in the 
body express the vitamin D receptor and can respond 
to circulating calcitriol.  Furthermore, it has been shown 
that many tissues, including the colon, pancreas, 
breast, prostate, immune system, macrophages, 
vascular endothelium, epidermis and placenta, 
possess the enzymes to produce 1,25(OH)2 vitamin D 
locally. This may explain why vitamin D appears to play 
an essential role in overall health.3,4
Measurement of vitamin D status
The 25(OH)D level best reflects the body’s overall 
vitamin D status, as it is more stable than 1,25(OH)2 
vitamin D, with a much longer half-life.5 The level 
reflects both dietary intake and sunlight exposure, 
as well as converted vitamin D, previously stored in 
fat. However, 25(OH)D assays are not standardised 
at the present time. It is essential for the clinician to 
use method-specific reference ranges and carry out 
patient follow-up at the same laboratory.
Vitamin D deficiency
Currently, normal vitamin D status is defined as a 
25(OH)D serum level of > 30 ng/ml (> 75 nmol/l). The 
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World Health Organization previously defined (true) 
deficiency as levels below 10 ng/ml (< 25 nmol/l).5 
However, the lower limit of normal still remains a 
topic of much debate. More recently, the term 
“vitamin D insufficiency” has been introduced to 
describe suboptimal levels (typically between 10 and 
30 ng/ml (25-75 nmol/l) of 25(OH)D associated with 
adverse outcomes2,5 (Table I).
Various reviews have described functional measures 
that are used to evaluate the adequacy of vitamin D 
levels.1,2
Table I: Interpretation of 25-hydroxyvitamin D 25 (OH) vitamin D 
level
Normal status > 30 ng/ml (75 nmol/l)
Vitamin D insufficiency 10-30 ng/ml
25-75 nmol/l
Vitamin D deficiency < 10 ng/ml
< 25 nmol/l
These include the 25(OH)D level at which there is 
maximal intestinal calcium reabsorption and no further 
increase in 1,25(OH)2 vitamin D levels with replacement 
and the level which maximally suppresses parathyroid 
hormone (PTH) secretion. The measurement of 25(OH)
D is the most suitable indicator of vitamin D status.2 In 
a South African study, it was found that PTH levels rose 
significantly once the 25(OH)D level dropped below 
10 mg/ml (25 nmol/l), but that more than half these 
patients still had calcium levels in the normal range.6
There has been a substantial increase in the 
prevalence of vitamin D deficiency in the past few 
years, as demonstrated by population-based studies 
like the National Health and Nutrition Examination 
Survey (NHANES) in the USA, where 25-30% of the 
population had frank vitamin D deficiency.1 This was 
noted across all age groups. Males and females were 
equally affected and non-Caucasoid populations 
were at the highest risk. Associated factors with this 
decline in vitamin D levels include a decrease in the 
intake of milk products, more liberal sunscreen use and 
sun avoidance, race, season, as well as the global 
increase in the prevalence of obesity.1
Diseases and outcomes associated with vitamin 
D deficiency
The classic outcomes of vitamin D deficiency are 
nutritional rickets (affecting growing bone) and 
osteomalacia (in adults). However, recently, it has 
become apparent that there are numerous other 
skeletal, as well as interesting nonskeletal benefits in 
having adequate vitamin D levels.2
These will be discussed here.
Skeletal health
Vitamin D is critical for bone health. Vitamin D levels 
are often lower in those who fracture. However, trials 
that assess the effectiveness of supplementation mostly 
include the addition of calcium as well. A Cochrane 
meta-analysis found no significant effect of vitamin 
D supplementation alone on the risk of fractures, but 
supplementation with both calcium and Vitamin D had 
a positive effect on the reduction of hip fractures in frail 
and institutionalised people.7
Observational studies indicate that there is an increased 
risk of falls in institutionalised persons that is associated 
with low vitamin D levels.8 This risk is also associated with 
poorer physical performance in community-dwelling 
older individuals and is a predictor of adverse events.9 
Vitamin D supplementation reduces the risk of falls in 
older adults through effects on muscle and the nervous 
system (both central and peripheral), whereby it 
improves gait and balance.8,10
Vitamin D supplementation of > 800 IU per day, aiming 
to achieve 25(OH)D levels of at least 30 ng/ml, was 
somewhat favourable in preventing hip fractures and 
nonvertebral fractures in persons who were 65 years 
and older.11
Cardiovascular health
Observational data have linked vitamin D deficiency 
with a range of cardiovascular diseases, which include 
strokes, myocardial infarction and hypertension.12-14 
Recently, a large study found reduced cardiovascular 
survival in vitamin D-deficient patients. Supplementing 
these patients was significantly associated with 
better survival.15 Interventional studies like these are 
encouraging, but many questions remain regarding 
dosing and optimal levels, as well as the issue of 
concomitant calcium supplementation (which is 
somewhat contentious at present).15
Diabetes mellitus
Low vitamin D is a risk factor for the development of 
type 1 diabetes mellitus, based on animal and human 
observational studies. Increased vitamin D intake is a 
possible preventative strategy for the disease.16 This may 
relate to the immunomodulatory actions of vitamin D, 
which influences lymphocytes and interleukins.17
Observational data suggest that altered vitamin 
D and calcium metabolism may also play a role 
in the development of type 2 diabetes mellitus.18,19 
Our understanding of the exact mechanisms for this 
association remains incomplete and is an area of 
active research. Vitamin D receptors and binding 
proteins are present in pancreatic islet tissue. The role 
of vitamin D in the pathogenesis of diabetes seems 
relate to its role in the regulation of plasma calcium, 
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which in turn regulates insulin secretion. In addition, it 
also has a direct effect on pancreatic B cells, as well 
as effects on inflammatory mediators.17,20 It has been 
demonstrated that obesity (a known risk factor for type 
2 diabetes mellitus) is associated with low vitamin D 
levels. However, interventional studies showing benefit 
are still lacking at this stage.21
Skin diseases
In a country renowned for its sunshine, the beneficial as 
well as harmful effects of ultraviolet (UV) radiation are 
apparent. Protection against UV radiation is advocated 
in order to reduce the risk of cancer, although this can 
lead to a marked reduction in vitamin D levels.22 Further 
work is necessary to define the adequate amount of sun 
exposure to obtain optimal vitamin D levels, especially 
in the South African climate. However, it is imperative 
that a balanced view is maintained of the positive 
(vitamin D) and negative (skin cancer risk) effects of 
UV radiation. Monitoring and supplementation with 
vitamin D is essential in patients at risk of developing 
vitamin D deficiency (the elderly and people who 
cover up for religious reasons).23 Interestingly, topical 
vitamin D derivatives are also used in the treatment of 
psoriasis.24
Infectious diseases and immunity
The relationship between vitamin D and the immune 
system was recognised a number of years ago with 
the demonstration of increased circulating levels of 
1,25(OH)2D and hypercalcuria and hypercalcaemia 
in sarcoidosis. This is because of the increased local 
activity of 1-α-hydroxylase which is found in activated 
macrophages.25 It is now clear that dysregulation of 
vitamin D homeostasis is not only present in sarcoidosis, 
but also in other forms of granulomatous disease and 
cancer.
Today, it is recognised that vitamin D plays a more 
active role in the immune system.26 It is involved in the 
differentiation of monocytes to mature phagocytic 
macrophages, and more recently, has been 
demonstrated to affect the phagocytic process by 
stimulating the expression of the antibacterial protein, 
cathelicidin.27 Regulation of this protein has also been 
described in other cell types, notably keratinocytes, 
lung epithelial cells, myeloid cells and placental 
trophoblasts.26
Low-serum vitamin D levels are associated with a 
higher risk of active tuberculosis.28 Considerable 
work has been carried out into the role of vitamin D 
supplementation in the management of tuberculosis, 
but to date the results have been conflicting. It has not 
been demonstrated to have a convincing effect on 
sputum conversion or mortality.29,30
Vitamin D deficiency is also very prevalent in human 
immunodeficiency virus (HIV)-infected individuals.31 
It has been shown that there is inadequate 
1-α-hydroxylation and decreased levels of 1,25(OH)2, 
possibly because of increased levels of TNF-α. This 
may contribute to the impaired immune response and 
the pathogenesis of HIVrelated immunodeficiency.32 
Moreover, non-nucleoside reverse transcriptase 
inhibitors, notably efavirenz, have been implicated in 
lowering vitamin D levels.33
Observational epidemiological studies have shown an 
increased risk of other viral infections (influenza and 
respiratory tract infections) associated with vitamin D 
deficiency.34
Cancer risk
The active form of vitamin D, calcitriol, has been shown 
to slow tumour growth in animal models.35 Various 
mechanisms are postulated, including inhibition of 
cell proliferation and enhanced apoptosis, inhibiting 
angiogenesis and suppressing inflammation and 
metastases. Observational studies also show vitamin D 
deficiency to be associated with an increased risk of 
developing cancer, notably breast, colon and prostate 
cancer.36 As a result of encouraging preclinical data, 
vitamin D has been studied extensively as an anti-
cancer drug, but the results have been disappointing 
to date.37
Rheumatologic diseases
Vitamin D is thought to protect against rheumatic 
diseases [rheumatoid arthritis (RA) and systemic lupus 
erythematosus (SLE)] through its effects on immune 
tolerance.27 A lower vitamin D level is associated with 
more severe and active disease in RA.38 The seasonal 
variation in vitamin D levels (lower in winter and higher 
in summer) negatively correlates with disease activity 
both in RA and SLE.22,24,39
Other diseases
Vitamin D deficiency has also been associated with 
various other diseases, including multiple sclerosis,40 
asthma,41 schizophrenia,42 gastrointestinal and liver 
disease43 and dementia.44
So how much is enough?
There is little consensus in the literature regarding the 
exact dosing, as well as optimal route of administration 
that is most beneficial. It is recommended that vitamin 
D supplementation should not be offered routinely, but 
that individuals at risk of deficiency (Table II) should be 
screened. In cases of severe deficiency, large doses 
(e.g. a once-weekly dose of 50 000 IU of D2 or D3 for 
six weeks, followed by a maintenance dose of 400-
1000 IU per day) may be required, and this may even 
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increase in obese patients, patients with malabsorption 
syndromes and patients on medication that affects 
vitamin D metabolism.45
















Acquired immune deficiency syndrome
Antifungals, e.g. ketoconazole
Cholestyramine
Pregnant and lactating women
Older adults with a history of falls and nontraumatic fracture
Obese adults and children (body mass index > 30 kg/m2)
Conclusion
Vitamin D deficiency has been linked to a number of 
diseases. However, until now, interventional studies 
have been fairly disappointing, other than proving 
that vitamin D is beneficial in skeletal disease. There is 
still some debate regarding the recommended daily 
allowance and the required optimal dose for standard 
supplementation, but meeting daily requirements 
in adults of 800-1000 IU should be adequate in most 
people who are at risk of vitamin D deficiency.
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